These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 20199181

  • 41. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
    Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM.
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
    [Abstract] [Full Text] [Related]

  • 42. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators.
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [Abstract] [Full Text] [Related]

  • 43. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment.
    Hayashi K, Kumagai H, Saruta T.
    Am J Hypertens; 2003 Feb; 16(2):116-22. PubMed ID: 12559677
    [Abstract] [Full Text] [Related]

  • 44. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.
    Tisaire-Sánchez J, Roma J, Camacho-Azcargorta I, Bueno-Gómez J, Mora-Maciá J, Navarro A.
    Vasc Health Risk Manag; 2006 Feb; 2(4):491-8. PubMed ID: 17323604
    [Abstract] [Full Text] [Related]

  • 45. Potential role of urinary angiotensinogen in predicting antiproteinuric effects of angiotensin receptor blocker in non-diabetic chronic kidney disease patients: a preliminary report.
    Jang HR, Lee YJ, Kim SR, Kim SG, Jang EH, Lee JE, Huh W, Kim YG.
    Postgrad Med J; 2012 Apr; 88(1038):210-6. PubMed ID: 22357774
    [Abstract] [Full Text] [Related]

  • 46. A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
    Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F, Remuzzi G, Ruggenenti P.
    Nephron; 2015 Apr; 130(1):13-20. PubMed ID: 25895746
    [Abstract] [Full Text] [Related]

  • 47. [Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension and metabolic disorders (review)].
    Tabidze GA, Gezeli TD, Tsibadze TA, Dolidze NM.
    Georgian Med News; 2015 Feb; (239):51-6. PubMed ID: 25802450
    [Abstract] [Full Text] [Related]

  • 48. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
    Kojima S, Shida M, Yokoyama H.
    Hypertens Res; 2004 Jun; 27(6):379-85. PubMed ID: 15253102
    [Abstract] [Full Text] [Related]

  • 49. Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study.
    Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D'Angelo A, Maffioli P.
    J Am Soc Hypertens; 2014 Jun; 8(6):422-8. PubMed ID: 24836352
    [Abstract] [Full Text] [Related]

  • 50. Current perspective on the use of calcium channel blockers to treat hypertensive patients: the role of lercanidipine.
    Mancia G, Tsioufis K.
    Future Cardiol; 2019 Jul; 15(4):259-266. PubMed ID: 31180724
    [Abstract] [Full Text] [Related]

  • 51. Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril.
    Ferri N, Corsini A, Pontremoli R.
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7482-7492. PubMed ID: 36314318
    [Abstract] [Full Text] [Related]

  • 52. Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.
    De Nicola L, Conte G, Russo D, Gorini A, Minutolo R.
    BMC Nephrol; 2012 Nov 20; 13():150. PubMed ID: 23167771
    [Abstract] [Full Text] [Related]

  • 53. Cardiovascular therapy in patients with renal insufficiency.
    Ruilope LM, Segura J.
    Cardiovasc Drugs Ther; 2002 Dec 20; 16(6):497-501. PubMed ID: 12766382
    [Abstract] [Full Text] [Related]

  • 54. Antiproteinuric effects of cilnidipine.
    Staessen JA.
    Kidney Int; 2008 May 20; 73(9):1095; author reply 1095-6. PubMed ID: 18414444
    [No Abstract] [Full Text] [Related]

  • 55. [Effect of renin-angiotensin system in Fabry disease associated proteinuria].
    Pagán Muñoz B, López-Rodríguez M, Gómez Cerezo JF, Poyatos Toribio C, Barbado Hernández FJ.
    Rev Clin Esp; 2007 Mar 20; 207(3):125-8. PubMed ID: 17397632
    [Abstract] [Full Text] [Related]

  • 56. [Nephroprotective effect of calcium channel blocker lercanidipine in treatment of patients with urolithiasis and urinary tract obstruction and monitoring of the serum cytokine profile].
    Khotko AI, Khotko DN, Zakharova NB, Tarasenko AI, Popkov VM, Alekseev AV.
    Urologiia; 2019 Dec 20; (5):48-52. PubMed ID: 31808632
    [Abstract] [Full Text] [Related]

  • 57. Antiproteinuric effect of ACE inhibitors.
    Heeg JE, de Zeeuw D, de Jong PE.
    Lancet; 1988 Nov 26; 2(8622):1251-2. PubMed ID: 2903981
    [No Abstract] [Full Text] [Related]

  • 58. Renal protection with calcium antagonists: the role of lercanidipine.
    Burnier M.
    Curr Med Res Opin; 2013 Dec 26; 29(12):1727-35. PubMed ID: 24069902
    [Abstract] [Full Text] [Related]

  • 59. Lercanidipine in the Management of Hypertension: An Update.
    Grassi G, Robles NR, Seravalle G, Fici F.
    J Pharmacol Pharmacother; 2017 Dec 26; 8(4):155-165. PubMed ID: 29472747
    [Abstract] [Full Text] [Related]

  • 60. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study.
    Robles NR, Calvo C, Sobrino J, Espinel E, Esteban R, Mateos L, Macias JF.
    Curr Med Res Opin; 2016 Oct 26; 32(sup2):29-34. PubMed ID: 27779460
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.